Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease (NCT06878495) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease
100 participantsStarted 2025-06-15
Plain-language summary
This study aims to evaluate the long-term outcomes of discontinuing 5-ASA in UC and CD patients receiving stable biologic or immunomodulator therapy using a prospective cohort based in the Busan-Ulsan-Gyeongnam region. It seeks to determine whether discontinuing 5-ASA is a safe treatment strategy in modern IBD management.
Who can participate
Age range19 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnosis
✓. Treatment Status
✓. Disease Activity
✓. Age
✓. Informed Consent
✓. Compliance with Study Protocol
✓. General Health Condition
✓. No recent medication changes
Exclusion criteria
✕. Patients with severe active UC or CD at the time of study enrollment.
✕. Patients who have been recently hospitalized for IBD-related reasons or undergone IBD-related surgery within three months before enrollment.
✕. Patients who have had dose modifications of biologics, immunomodulators, or corticosteroids for IBD within three months before enrollment.
✕. Patients receiving concomitant therapy with other medications that may affect disease activity (e.g., additional anti-inflammatory agents, IBD-related antibiotics).
✕. Patients with severe cardiac, renal, or hepatic disease or other medical conditions that could interfere with the study.
✕. Pregnant or breastfeeding women.
What they're measuring
1
Disease relapse rate
Timeframe: Through study completion, an average of 9 months